JP2022529945A5 - - Google Patents
Info
- Publication number
- JP2022529945A5 JP2022529945A5 JP2021561673A JP2021561673A JP2022529945A5 JP 2022529945 A5 JP2022529945 A5 JP 2022529945A5 JP 2021561673 A JP2021561673 A JP 2021561673A JP 2021561673 A JP2021561673 A JP 2021561673A JP 2022529945 A5 JP2022529945 A5 JP 2022529945A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- mutations
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962835343P | 2019-04-17 | 2019-04-17 | |
| US62/835,343 | 2019-04-17 | ||
| PCT/US2020/028540 WO2020214824A1 (en) | 2019-04-17 | 2020-04-16 | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529945A JP2022529945A (ja) | 2022-06-27 |
| JP2022529945A5 true JP2022529945A5 (https=) | 2023-04-24 |
| JP7709384B2 JP7709384B2 (ja) | 2025-07-16 |
Family
ID=72837936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561673A Active JP7709384B2 (ja) | 2019-04-17 | 2020-04-16 | チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220175779A1 (https=) |
| EP (1) | EP3956035A4 (https=) |
| JP (1) | JP7709384B2 (https=) |
| KR (1) | KR20220004089A (https=) |
| CN (1) | CN113993592A (https=) |
| AU (1) | AU2020257395A1 (https=) |
| BR (1) | BR112021020601A2 (https=) |
| CA (1) | CA3132819A1 (https=) |
| IL (1) | IL287115A (https=) |
| MX (1) | MX2021012705A (https=) |
| PH (1) | PH12021552579A1 (https=) |
| SG (1) | SG11202111120VA (https=) |
| WO (1) | WO2020214824A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| WO2022165219A1 (en) * | 2021-01-29 | 2022-08-04 | Board Of Regents, The University Of Texas System | Methods of treating cancer with poziotinib |
| US20240384350A1 (en) * | 2021-01-29 | 2024-11-21 | Board Of Regents, The University Of Texas System | Methods of treating cancer with kinase inhibitors |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| CN115998743B (zh) * | 2023-01-16 | 2024-05-28 | 威尚（上海）生物医药有限公司 | 喹唑啉类化合物在克服奥希替尼耐药中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| WO2017198602A1 (en) * | 2016-05-18 | 2017-11-23 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| US20180333415A1 (en) * | 2017-05-19 | 2018-11-22 | Regents Of The University Of Minnesota | Therapeutic methods |
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| CA3101657A1 (en) * | 2018-06-25 | 2020-01-02 | Spectrum Pharmaceuticals, Inc. | Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof |
| WO2020055643A2 (en) * | 2018-09-04 | 2020-03-19 | Rain Therapeutics Inc. | Compounds, compositions and methods for treating or preventing her-driven cancers |
| BR112021016149A2 (pt) * | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MX2021011925A (es) * | 2019-03-29 | 2021-11-03 | Univ Texas | Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano. |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
-
2020
- 2020-04-16 EP EP20792247.7A patent/EP3956035A4/en active Pending
- 2020-04-16 AU AU2020257395A patent/AU2020257395A1/en not_active Abandoned
- 2020-04-16 WO PCT/US2020/028540 patent/WO2020214824A1/en not_active Ceased
- 2020-04-16 KR KR1020217037150A patent/KR20220004089A/ko not_active Ceased
- 2020-04-16 MX MX2021012705A patent/MX2021012705A/es unknown
- 2020-04-16 US US17/604,560 patent/US20220175779A1/en active Pending
- 2020-04-16 CN CN202080044361.XA patent/CN113993592A/zh active Pending
- 2020-04-16 BR BR112021020601A patent/BR112021020601A2/pt not_active Application Discontinuation
- 2020-04-16 JP JP2021561673A patent/JP7709384B2/ja active Active
- 2020-04-16 CA CA3132819A patent/CA3132819A1/en active Pending
- 2020-04-16 SG SG11202111120VA patent/SG11202111120VA/en unknown
- 2020-04-16 PH PH1/2021/552579A patent/PH12021552579A1/en unknown
-
2021
- 2021-10-10 IL IL287115A patent/IL287115A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529945A5 (https=) | ||
| JP2022529016A5 (https=) | ||
| JP2022527788A5 (https=) | ||
| JP7265985B2 (ja) | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 | |
| US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| Ponti et al. | BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival | |
| JP2020502059A5 (https=) | ||
| JP2021517894A5 (https=) | ||
| JP2022071099A5 (https=) | ||
| CN114728005A (zh) | Bi853520在癌症治疗中的用途 | |
| JP2022527499A5 (https=) | ||
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| Cavic et al. | Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia | |
| TW202216149A (zh) | 用於治療非小細胞肺癌之ｅｇｆｒ ｔｋｉ | |
| CN103764847B (zh) | 对于kras基因突变型的结肠直肠癌患者的抗肿瘤剂和治疗效果预测方法 | |
| JP2021519306A5 (https=) | ||
| JP2022515128A5 (https=) | ||
| ES3054788T3 (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| Grellety et al. | A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy | |
| CN115698338A (zh) | 用妥卡替尼治疗her2突变型癌症的方法 | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Ahmed et al. | Therapeutic Insights Into a Case-Control Approach to B-cell Lymphoma 3 (BCL3)-Encoded Protein by Exploring Immune Modulation and Clinical Strategies in Oral Carcinomas | |
| JP7430890B2 (ja) | 置換ブテンアミドの応用 | |
| RU2021133154A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации egfr, резистентные к ингибитору тирозинкиназы |